On May 15, 2020 ImmunSYS, Inc., a clinical- stage biopharmaceutical company focused on the development of innovative cancer immunotherapy products, reported that results from a proof of concept (PoC) study evaluating its proprietary immunotherapy platform, YourVaccx, for the treatment of patients with metastatic solid tumor cancers will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) 2020 Virtual Annual Meeting II being held June 22 – 24 (Press release, ImmunSYS, MAY 15, 2020, View Source;utm_medium=rss&utm_campaign=immunsys-announces-upcoming-presentation-at-aacr-virtual-annual-meeting-ii [SID1234558146]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The poster (#6540) entitled, "Regression of metastatic cancer and abscopal effects following in situ vaccination by cryosurgical tumor cell lysis and intratumoral immunotherapy: A case series" will be presented by Gary Onik, M.D.
ImmunSYS’s abstract can be found at www.aacr.org
Following the presentation, a copy of the poster will be posted on www.immunsys.com